Sonnet biotherapeutics successfully completes first safety review of son-1010 in combination with trabectedin in certain sarcomas

Son-1010 is being studied as a combination therapy with trabectedin (yondelis ® ), the first fda-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (pfs)
SONN Ratings Summary
SONN Quant Ranking